GSA Capital Partners LLP Invests $2.19 Million in CVS Health Corp (CVS) Stock
GSA Capital Partners LLP bought a new stake in CVS Health Corp (NYSE:CVS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 27,752 shares of the pharmacy operator’s stock, valued at approximately $2,185,000.
A number of other large investors have also recently modified their holdings of the business. BlackRock Inc. boosted its holdings in shares of CVS Health by 2.8% in the third quarter. BlackRock Inc. now owns 76,197,017 shares of the pharmacy operator’s stock valued at $5,998,231,000 after buying an additional 2,061,915 shares during the period. FMR LLC boosted its holdings in shares of CVS Health by 4.3% in the third quarter. FMR LLC now owns 30,069,260 shares of the pharmacy operator’s stock valued at $2,367,052,000 after buying an additional 1,250,473 shares during the period. Parnassus Investments CA boosted its holdings in shares of CVS Health by 2.2% in the second quarter. Parnassus Investments CA now owns 16,659,501 shares of the pharmacy operator’s stock valued at $1,072,039,000 after buying an additional 350,872 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of CVS Health by 15.9% in the second quarter. Bank of New York Mellon Corp now owns 12,573,338 shares of the pharmacy operator’s stock valued at $809,095,000 after buying an additional 1,721,683 shares during the period. Finally, Veritas Asset Management LLP boosted its holdings in shares of CVS Health by 4.5% in the second quarter. Veritas Asset Management LLP now owns 11,890,424 shares of the pharmacy operator’s stock valued at $765,149,000 after buying an additional 508,500 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.
Several research firms have recently weighed in on CVS. Cantor Fitzgerald began coverage on shares of CVS Health in a report on Monday, November 26th. They issued an “overweight” rating and a $96.00 price target for the company. ValuEngine upgraded shares of CVS Health from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. Loop Capital set a $80.00 price target on shares of CVS Health and gave the company a “hold” rating in a report on Wednesday, November 28th. Goldman Sachs Group reiterated a “neutral” rating and issued a $87.00 price target on shares of CVS Health in a report on Thursday, November 29th. Finally, Evercore ISI began coverage on shares of CVS Health in a report on Wednesday, November 28th. They issued an “outperform” rating and a $89.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $90.69.
CVS Health (NYSE:CVS) last announced its earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.71 by $0.02. CVS Health had a net margin of 1.65% and a return on equity of 18.69%. The business had revenue of $47.27 billion during the quarter, compared to analysts’ expectations of $47.22 billion. During the same quarter in the prior year, the company posted $1.50 earnings per share. The firm’s revenue was up 2.4% on a year-over-year basis. As a group, equities research analysts predict that CVS Health Corp will post 7.03 EPS for the current year.
In other CVS Health news, EVP Lisa Bisaccia sold 21,534 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $80.00, for a total value of $1,722,720.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Eva C. Boratto sold 13,311 shares of the stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the completion of the sale, the executive vice president now owns 55,162 shares of the company’s stock, valued at approximately $4,256,299.92. The disclosure for this sale can be found here. Insiders have sold 74,233 shares of company stock valued at $5,932,565 in the last 90 days. 0.53% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “GSA Capital Partners LLP Invests $2.19 Million in CVS Health Corp (CVS) Stock” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2018/12/07/gsa-capital-partners-llp-invests-2-19-million-in-cvs-health-corp-cvs-stock.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.